VERACYTE
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.
VERACYTE
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2006-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.veracyte.com
Total Employee:
501+
Status:
Active
Contact:
6502436301
Email Addresses:
[email protected]
Total Funding:
1.1 B USD
Technology used in webpage:
Domain Not Resolving Amazon Mobile Non Scaleable Content IPv6 ReCAPTCHA Organization Schema Wordpress Plugins U.S. Server Location CrUX Top 50m Common Name Invalid
Similar Organizations
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
LightDeck Diagnostics
LightDeck is a developer of on-the-spot diagnostic products used to offer fast, accurate, simple, and low-cost diagnostic tests.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Tandem Diabetes Care
Tandem diabetes care provides products that empower both people with diabetes and those who care for them.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-01-08 | C2i Genomics | C2i Genomics acquired by Veracyte | 70 M USD |
| 2021-06-01 | HalioDx | HalioDx acquired by Veracyte | 260 M EUR |
| 2021-02-03 | Decipher Biosciences | Decipher Biosciences acquired by Veracyte | 600 M USD |
| 2014-09-04 | Allegro Diagnostics | Allegro Diagnostics acquired by Veracyte | 21 M USD |
Investors List
Visium Healthcare Partners
Visium Healthcare Partners investment in Post-IPO Debt - Veracyte
Armentum Partners
Armentum Partners investment in Debt Financing - Veracyte
Domain Associates
Domain Associates investment in Series C - Veracyte
GE Ventures
GE Ventures investment in Series C - Veracyte
TPG Biotech
TPG Biotech investment in Series C - Veracyte
Versant Ventures
Versant Ventures investment in Series C - Veracyte
Kleiner Perkins
Kleiner Perkins investment in Series C - Veracyte
Kleiner Perkins
Kleiner Perkins investment in Venture Round - Veracyte
Domain Associates
Domain Associates investment in Venture Round - Veracyte
Versant Ventures
Versant Ventures investment in Series B - Veracyte
Newest Events participated
Participated in 3rd World Congress on Thyroid Cancer
on 2017-07-27 as exhibitor
Participated in 3rd World Congress on Thyroid Cancer
on 2017-07-27 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2023-09-27 | Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer |
| 2022-02-22 | Veracyte Appoints Jonathan Wygant as Chief Accounting Officer |
Official Site Inspections
http://www.veracyte.com Semrush global rank: 1.4 M Semrush visits lastest month: 18.2 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Veracyte"
Veracyte global diagnostics company
Feb 3, 2022 · Veracyte is a pioneering global diagnostics company. Our molecular tests empower clinicians with high-value insights in the race to diagnose and treat cancer.See details»
Who we are - Veracyte
Feb 3, 2022 · Veracyte is a global cancer diagnostics company. Our tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions.See details»
Governance overview - Veracyte, Inc.
Veracyte is committed to promoting ethical practices throughout our organization. Find key governance documents and committee charters.See details»
Leadership - Veracyte
Veracyte’s executive team members leverage their diverse expertise in life sciences and diagnostics to deliver transformational solutions for physicians and patients. Exceptional …See details»
Veracyte - Crunchbase Company Profile & Funding
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the …See details»
Veracyte and Gustave Roussy Announce Collaboration to Help ...
Sep 6, 2023 · Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high …See details»
Veracyte, Inc. - LinkedIn
Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat...See details»
Veracyte, Inc. Company Profile | South San Francisco, CA
Company Description: Veracyte is a global genomic diagnostics company that aims to improve patient care through better diagnosis and treatment decisions for patients with cancer and …See details»
Working at Veracyte Inc | Great Place To Work®
Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and …See details»
Working at Veracyte
Veracyte’s commitment to improving patient care is unwavering and would not be possible without our world-class team. We are a global organization united by our mission to address unmet clinical needs that stand in the way of better patient …See details»
Marc Stapley - CEO at Veracyte - The Org
Marc Stapley became Chief Executive Officer of Veracyte on June 1, 2021, and also serves on the company’s board of directors. Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise …See details»
Veracyte - Overview, News & Similar companies | ZoomInfo.com
Veracyte contact info: Phone number: (650) 243-6300 Website: www.veracyte.com What does Veracyte do? Founded in 2006, Veracyte is emerging in the field of molecular cytology by …See details»
Veracyte, Inc. | Investor Relations
6 days ago · Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to …See details»
Veracyte Company Profile - Office Locations, Competitors ... - Craft
Oct 28, 2024 · Veracyte has 5 employees across 5 locations and $361.05 m in annual revenue in FY 2023. See insights on Veracyte including office locations, competitors, revenue, financials, …See details»
Veracyte Announces Key Leadership Promotions to Advance Its …
Jan 6, 2022 · SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )-- Veracyte, Inc. (Nasdaq: VCYT) today announced key leadership promotions that further position the company to …See details»
Enabling global access for our tests - Veracyte
Veracyte intends to offer a broad menu of tests for use as IVDs to labs and hospitals outside of the US, enabling patients everywhere to access them. Today, our Prosigna ® Breast Cancer …See details»
Veracyte, Inc. Announces CEO Succession Plan | Business Wire
May 10, 2021 · Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions …See details»
Portfolio and test expansion - Veracyte
Veracyte is developing new tests to enable physicians to provide better cancer care at pivotal moments for patients. Our tests use pioneering science to address unmet needs and enable …See details»
Veracyte, Inc. | Veracyte Announces First Quarter 2022 Financial …
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022. "I am …See details»
Our approach to breast cancer diagnosis at Veracyte
Feb 3, 2022 · Learn about our exceptional breast cancer diagnostics. At Veracyte, we work closely with clinicians and researchers to understand how better testing technology could …See details»